Event Details

10^th June at 11:00-12:00
Onsite event
in Arhe Scheinin auditorium, Dentalia

Andy Chan
Evolving drug modalities from antibodies to in vivo cell programming to treat autoimmune diseases

Host: Timo Veromaa (timo.veromaa@utu.fi)

Coffee and sandwiches will be served before the seminar.

Dr. Andrew Chan is a former Senior Vice President of Research-Biology at Genentech, Inc where he oversaw biological research across all therapeutic areas including oncology, immunology, neuroscience, infectious diseases and regenerative medicine. He is a leader in biotherapeutics discovery and development and integrates lessons learned about disease pathogenesis and mechanisms of therapy. Chan’s research focuses on how our immune systems protect us against foreign pathogens and yet cause autoimmune and inflammatory diseases. Chan is also co-inventor of ocrelizumab (Ocrevus™), the first B-cell directed therapy approved by the FDA for treatment of both relapsing and progressive forms of multiple sclerosis.

Andy is also arranging Careers in science workshops
For doctoral researchers: Tuesday, June 9, at 14:00–15:30
For postdocs: Wednesday, June 10, at 13:00–14:30
Both workshops have limited room, so please register in advance. Coffee/tea and pulla will be included! Registration: https://link.webropol.com/s/chan-workshop.

And as usual, Andy is also available for 1-to-1 meetings. Reserve a time here: https://inflames.utu.fi/contact/reservation-calendars/